Medicus Pharma

Medicus Pharma Submits Optimized Teverelix Registrational Protocol to FDA

PHILADELPHIA — September 29, 2026 Medicus Pharma Ltd. announced that it has submitted an optimized seamless Phase 2b/3 registration-intent...

By cGxPwire Editor
September 30, 2026

Bio-Pharma

Medicus Pharma Advances Precision Oncology Strategy With CD228V

PHILADELPHIA, Pennsylvania — September 8, 2026 Medicus Pharma Ltd. announced a strategic transformation into a precision oncology-led biotechnology company,...

By cGxPwire Editor
September 8, 2026

.Clinical

Medicus Pharma Receives UAE IND Authorization for PRECISION-E2 Study

PHILADELPHIA, July 31, 2026 Medicus Pharma Ltd. announced that the United Arab Emirates (UAE) Department of Health – Abu...

By cGxPwire Editor
August 1, 2026

Bio-Pharma

Medicus Pharma Receives FDA Clearance for Registrational SkinJect Study

PHILADELPHIA, July 27, 2026 Medicus Pharma Ltd. announced that the U.S. Food and Drug Administration (FDA) has issued a...

By cGxPwire Editor
July 29, 2026

Bio-Pharma

Medicus Pharma Advances Optimized Phase 2 Teverelix Study

PHILADELPHIA, July 16, 2026 Medicus Pharma announced that it has received written feedback from the U.S. Food and Drug...

By cGxPwire Editor
July 17, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

Medicus Pharma Submits Optimized Teverelix Registrational Protocol to FDA

Medicus Pharma Advances Precision Oncology Strategy With CD228V

Medicus Pharma Receives UAE IND Authorization for PRECISION-E2 Study

Medicus Pharma Receives FDA Clearance for Registrational SkinJect Study

Medicus Pharma Advances Optimized Phase 2 Teverelix Study